Cargando…
Fecal Microbiota Transplant Mitigates Adverse Outcomes Seen in Patients Colonized With Multidrug-Resistant Organisms Undergoing Allogeneic Hematopoietic Cell Transplantation
The gut microbiome can be adversely affected by chemotherapy and antibiotics prior to hematopoietic cell transplantation (HCT). This affects graft success and increases susceptibility to multidrug-resistant organism (MDRO) colonization and infection. We performed an initial retrospective analysis of...
Autores principales: | , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8430254/ https://www.ncbi.nlm.nih.gov/pubmed/34513724 http://dx.doi.org/10.3389/fcimb.2021.684659 |
_version_ | 1783750666382999552 |
---|---|
author | Innes, Andrew J. Mullish, Benjamin H. Ghani, Rohma Szydlo, Richard M. Apperley, Jane F. Olavarria, Eduardo Palanicawandar, Renuka Kanfer, Edward J. Milojkovic, Dragana McDonald, Julie A. K. Brannigan, Eimear T. Thursz, Mark R. Williams, Horace R. T. Davies, Frances J. Marchesi, Julian R. Pavlů, Jiří |
author_facet | Innes, Andrew J. Mullish, Benjamin H. Ghani, Rohma Szydlo, Richard M. Apperley, Jane F. Olavarria, Eduardo Palanicawandar, Renuka Kanfer, Edward J. Milojkovic, Dragana McDonald, Julie A. K. Brannigan, Eimear T. Thursz, Mark R. Williams, Horace R. T. Davies, Frances J. Marchesi, Julian R. Pavlů, Jiří |
author_sort | Innes, Andrew J. |
collection | PubMed |
description | The gut microbiome can be adversely affected by chemotherapy and antibiotics prior to hematopoietic cell transplantation (HCT). This affects graft success and increases susceptibility to multidrug-resistant organism (MDRO) colonization and infection. We performed an initial retrospective analysis of our use of fecal microbiota transplantation (FMT) from healthy donors as therapy for MDRO-colonized patients with hematological malignancy. FMT was performed on eight MDRO-colonized patients pre-HCT (FMT-MDRO group), and outcomes compared with 11 MDRO colonized HCT patients from the same period. At 12 months, survival was significantly higher in the FMT-MDRO group (70% versus 36% p = 0.044). Post-HCT, fewer FMT-MDRO patients required intensive care (0% versus 46%, P = 0.045) or experienced fever (0.29 versus 0.11 days, P = 0.027). Intestinal MDRO decolonization occurred in 25% of FMT-MDRO patients versus 11% non-FMT MDRO patients. Despite the significant differences and statistically comparable patient/transplant characteristics, as the sample size was small, a matched-pair analysis between both groups to non-MDRO colonized control cohorts (2:1 matching) was performed. At 12 months, the MDRO group who did not have an FMT had significantly lower survival (36.4% versus 61.9% respectively, p=0.012), and higher non relapse mortality (NRM; 60.2% versus 16.7% respectively, p=0.009) than their paired non-MDRO-colonized cohort. Conversely, there was no difference in survival (70% versus 43.4%, p=0.14) or NRM (12.5% versus 31.2% respectively, p=0.24) between the FMT-MDRO group and their paired non-MDRO cohort. Collectively, these data suggest that negative clinical outcomes, including mortality associated with MDRO colonization, may be ameliorated by pre-HCT FMT, even in the absence of intestinal MDRO decolonization. Further work is needed to explore this observed benefit. |
format | Online Article Text |
id | pubmed-8430254 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-84302542021-09-11 Fecal Microbiota Transplant Mitigates Adverse Outcomes Seen in Patients Colonized With Multidrug-Resistant Organisms Undergoing Allogeneic Hematopoietic Cell Transplantation Innes, Andrew J. Mullish, Benjamin H. Ghani, Rohma Szydlo, Richard M. Apperley, Jane F. Olavarria, Eduardo Palanicawandar, Renuka Kanfer, Edward J. Milojkovic, Dragana McDonald, Julie A. K. Brannigan, Eimear T. Thursz, Mark R. Williams, Horace R. T. Davies, Frances J. Marchesi, Julian R. Pavlů, Jiří Front Cell Infect Microbiol Cellular and Infection Microbiology The gut microbiome can be adversely affected by chemotherapy and antibiotics prior to hematopoietic cell transplantation (HCT). This affects graft success and increases susceptibility to multidrug-resistant organism (MDRO) colonization and infection. We performed an initial retrospective analysis of our use of fecal microbiota transplantation (FMT) from healthy donors as therapy for MDRO-colonized patients with hematological malignancy. FMT was performed on eight MDRO-colonized patients pre-HCT (FMT-MDRO group), and outcomes compared with 11 MDRO colonized HCT patients from the same period. At 12 months, survival was significantly higher in the FMT-MDRO group (70% versus 36% p = 0.044). Post-HCT, fewer FMT-MDRO patients required intensive care (0% versus 46%, P = 0.045) or experienced fever (0.29 versus 0.11 days, P = 0.027). Intestinal MDRO decolonization occurred in 25% of FMT-MDRO patients versus 11% non-FMT MDRO patients. Despite the significant differences and statistically comparable patient/transplant characteristics, as the sample size was small, a matched-pair analysis between both groups to non-MDRO colonized control cohorts (2:1 matching) was performed. At 12 months, the MDRO group who did not have an FMT had significantly lower survival (36.4% versus 61.9% respectively, p=0.012), and higher non relapse mortality (NRM; 60.2% versus 16.7% respectively, p=0.009) than their paired non-MDRO-colonized cohort. Conversely, there was no difference in survival (70% versus 43.4%, p=0.14) or NRM (12.5% versus 31.2% respectively, p=0.24) between the FMT-MDRO group and their paired non-MDRO cohort. Collectively, these data suggest that negative clinical outcomes, including mortality associated with MDRO colonization, may be ameliorated by pre-HCT FMT, even in the absence of intestinal MDRO decolonization. Further work is needed to explore this observed benefit. Frontiers Media S.A. 2021-08-27 /pmc/articles/PMC8430254/ /pubmed/34513724 http://dx.doi.org/10.3389/fcimb.2021.684659 Text en Copyright © 2021 Innes, Mullish, Ghani, Szydlo, Apperley, Olavarria, Palanicawandar, Kanfer, Milojkovic, McDonald, Brannigan, Thursz, Williams, Davies, Marchesi and Pavlů https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Cellular and Infection Microbiology Innes, Andrew J. Mullish, Benjamin H. Ghani, Rohma Szydlo, Richard M. Apperley, Jane F. Olavarria, Eduardo Palanicawandar, Renuka Kanfer, Edward J. Milojkovic, Dragana McDonald, Julie A. K. Brannigan, Eimear T. Thursz, Mark R. Williams, Horace R. T. Davies, Frances J. Marchesi, Julian R. Pavlů, Jiří Fecal Microbiota Transplant Mitigates Adverse Outcomes Seen in Patients Colonized With Multidrug-Resistant Organisms Undergoing Allogeneic Hematopoietic Cell Transplantation |
title | Fecal Microbiota Transplant Mitigates Adverse Outcomes Seen in Patients Colonized With Multidrug-Resistant Organisms Undergoing Allogeneic Hematopoietic Cell Transplantation |
title_full | Fecal Microbiota Transplant Mitigates Adverse Outcomes Seen in Patients Colonized With Multidrug-Resistant Organisms Undergoing Allogeneic Hematopoietic Cell Transplantation |
title_fullStr | Fecal Microbiota Transplant Mitigates Adverse Outcomes Seen in Patients Colonized With Multidrug-Resistant Organisms Undergoing Allogeneic Hematopoietic Cell Transplantation |
title_full_unstemmed | Fecal Microbiota Transplant Mitigates Adverse Outcomes Seen in Patients Colonized With Multidrug-Resistant Organisms Undergoing Allogeneic Hematopoietic Cell Transplantation |
title_short | Fecal Microbiota Transplant Mitigates Adverse Outcomes Seen in Patients Colonized With Multidrug-Resistant Organisms Undergoing Allogeneic Hematopoietic Cell Transplantation |
title_sort | fecal microbiota transplant mitigates adverse outcomes seen in patients colonized with multidrug-resistant organisms undergoing allogeneic hematopoietic cell transplantation |
topic | Cellular and Infection Microbiology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8430254/ https://www.ncbi.nlm.nih.gov/pubmed/34513724 http://dx.doi.org/10.3389/fcimb.2021.684659 |
work_keys_str_mv | AT innesandrewj fecalmicrobiotatransplantmitigatesadverseoutcomesseeninpatientscolonizedwithmultidrugresistantorganismsundergoingallogeneichematopoieticcelltransplantation AT mullishbenjaminh fecalmicrobiotatransplantmitigatesadverseoutcomesseeninpatientscolonizedwithmultidrugresistantorganismsundergoingallogeneichematopoieticcelltransplantation AT ghanirohma fecalmicrobiotatransplantmitigatesadverseoutcomesseeninpatientscolonizedwithmultidrugresistantorganismsundergoingallogeneichematopoieticcelltransplantation AT szydlorichardm fecalmicrobiotatransplantmitigatesadverseoutcomesseeninpatientscolonizedwithmultidrugresistantorganismsundergoingallogeneichematopoieticcelltransplantation AT apperleyjanef fecalmicrobiotatransplantmitigatesadverseoutcomesseeninpatientscolonizedwithmultidrugresistantorganismsundergoingallogeneichematopoieticcelltransplantation AT olavarriaeduardo fecalmicrobiotatransplantmitigatesadverseoutcomesseeninpatientscolonizedwithmultidrugresistantorganismsundergoingallogeneichematopoieticcelltransplantation AT palanicawandarrenuka fecalmicrobiotatransplantmitigatesadverseoutcomesseeninpatientscolonizedwithmultidrugresistantorganismsundergoingallogeneichematopoieticcelltransplantation AT kanferedwardj fecalmicrobiotatransplantmitigatesadverseoutcomesseeninpatientscolonizedwithmultidrugresistantorganismsundergoingallogeneichematopoieticcelltransplantation AT milojkovicdragana fecalmicrobiotatransplantmitigatesadverseoutcomesseeninpatientscolonizedwithmultidrugresistantorganismsundergoingallogeneichematopoieticcelltransplantation AT mcdonaldjulieak fecalmicrobiotatransplantmitigatesadverseoutcomesseeninpatientscolonizedwithmultidrugresistantorganismsundergoingallogeneichematopoieticcelltransplantation AT branniganeimeart fecalmicrobiotatransplantmitigatesadverseoutcomesseeninpatientscolonizedwithmultidrugresistantorganismsundergoingallogeneichematopoieticcelltransplantation AT thurszmarkr fecalmicrobiotatransplantmitigatesadverseoutcomesseeninpatientscolonizedwithmultidrugresistantorganismsundergoingallogeneichematopoieticcelltransplantation AT williamshoracert fecalmicrobiotatransplantmitigatesadverseoutcomesseeninpatientscolonizedwithmultidrugresistantorganismsundergoingallogeneichematopoieticcelltransplantation AT daviesfrancesj fecalmicrobiotatransplantmitigatesadverseoutcomesseeninpatientscolonizedwithmultidrugresistantorganismsundergoingallogeneichematopoieticcelltransplantation AT marchesijulianr fecalmicrobiotatransplantmitigatesadverseoutcomesseeninpatientscolonizedwithmultidrugresistantorganismsundergoingallogeneichematopoieticcelltransplantation AT pavlujiri fecalmicrobiotatransplantmitigatesadverseoutcomesseeninpatientscolonizedwithmultidrugresistantorganismsundergoingallogeneichematopoieticcelltransplantation |